ENVB

ENVB

USD

Enveric Biosciences Inc. Common Stock

$5.700-0.400 (-6.557%)

Real-time Price

Healthcare
Biotechnology
United States

Price Chart

Loading Chart...

Key Metrics

Market Metrics
Company Fundamentals
Trading Stats

Market Metrics

Open

$6.100

High

$6.645

Low

$5.520

Volume

0.25M

Company Fundamentals

Market Cap

3.0M

Industry

Biotechnology

Country

United States

Trading Stats

Avg Volume

0.07M

Exchange

NCM

Currency

USD

52-Week Range

Low $5.52Current $5.700High $1444.5

Related News

BusinessWire

Enveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND Submission

Enveric expects to file Investigational New Drug application for EB-003 in early 2026 Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic

View more
Enveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND Submission
BusinessWire

Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference

Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced that

View more
Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference
BusinessWire

Enveric Biosciences Relocates Corporate Headquarters to Cambridge, MA

Move aligns with company's vision to leverage the Greater Boston biotech hub's scientific and financial ecosystem and advance EB-003 into first-in-human trial in 2026 Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or

View more
Enveric Biosciences Relocates Corporate Headquarters to Cambridge, MA
BusinessWire

Enveric Biosciences Successfully Completes Pre-IND Dose Range Finding Studies for Lead Candidate EB-003, Targeting Neuropsychiatric Indications

Data establish maximum tolerated dose, supporting progression of lead neuroplastogen compound EB-003 toward IND-enabling studies and First-in-Human clinical trials Enveric Biosciences, Inc. (NASDAQ:ENVB) ("Enveric" or

View more
Enveric Biosciences Successfully Completes Pre-IND Dose Range Finding Studies for Lead Candidate EB-003, Targeting Neuropsychiatric Indications